Novavax delays US trial of Covid-19 vaccine candidate to November


Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.

The US-based drug developer said data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021 and could be the basis for regulatory approval, sending its shares up 3.4% in early trading. Data from an early-to-mid stage or phase 2 trial of the vaccine is now expected on Friday, the company.

This article is no longer available in our repository.

There could be multiple reasons for this.